Zimbabwe has turned down a major American healthcare agreement worth $367m (272 million pounds) spanning five years because of the United States' request for sensitive data.
This rejection became public after a internal memorandum dated December was disclosed, indicating that President Emmerson Mnangagwa felt the agreement was "unbalanced".
A government spokesman has since clarified that the US was requesting genetic material for scientific study and commercial purposes while was unwilling to guarantee the benefits from future treatments.
"We are forced to start the challenging and unfortunate process of ending our health aid in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the US had furnished more than $1.9bn in health funding to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has urged further dialogue to reach a deal agreeable to both sides so the country's critical HIV programme can be sustained.
Broader Background
This development follows a comparable case in neighbouring Kenya, where a court blocked a similar health funding agreement after legal challenges were raised about the safety of citizens' medical information.
Since resuming office recently, US President Donald Trump has slashed foreign aid and closed the key foreign aid agency.
USAID had administered assistance for the US government, but Trump claimed its expenditure was "wasteful" and his administration was seeking direct bilateral agreements to enhance openness and accountability.
According to statements, Sixteen African countries have to date agreed to these new health pacts, representing over $18.3bn in new funding.
Details of the Declined Deal
The money for Zimbabwe would have funded "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this partnership would have delivered immense advantages for the people of Zimbabwe, especially the 1.2 million currently receiving HIV treatment through US-supported programmes," Tremont added.
However, official spokesman Nick Mangwana argued the proposed deal was "unequal".
"Zimbabwe was being asked to surrender its genetic material and health information indefinitely, with no equivalent assurance of benefiting from any medical innovations – such as new medicines or tests – that might be developed from that shared data," his statement read.
"In essence, our country would provide the basic resources for scientific discovery without any certainty that the final treatments would be accessible to our people if a future pandemic arise."
National Interest and Global Health
He also pointed out that the US's withdrawal from the global health body and its push of bilateral deals were undermining frameworks previously set up through the international health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing scheme designed to manage potential pandemics.
"This system is designed to guarantee that when a nation provides its information, the benefits – including medicines and cures – are shared equitably, not monopolised solely by those with the capability to develop them."
Zimbabwe's reservations over the US deal "are not meant as anti-American sentiment," he added.
"We are open to ongoing discussions with our US partners on how subsequent collaboration could be designed in a way that honours the sovereignty and interests of each country."
Health Experts Response
Medical experts expressed it acknowledged the government's concerns, but suggested that negotiations must proceed given that much of the country's HIV programmes depended on external financing.
"In cases where technical issues exist, such as those involving data governance or agreement terms, these can often be addressed through technical clarification and negotiated safeguards," the group commented.
The situation emphasises the ongoing tensions between receiving much-needed international aid and safeguarding local interests in an ever more data-driven world.